The Biotechnology Innovation Organization (BIO) is pleased to announce that the Honorable Dennis McGinn, Assistant Secretary of the Navy, Energy, Installations...
BIO Executive Vice President for Health Policy Dan Durham released the following statement regarding yesterday’s proposed Part B Drug Payment Model and...

Press Releases

Apr 14 2016
Washington, D.C. (April 13, 2016) – The Biotechnology Innovation Organization (BIO) announced today its selection of Congressman Patrick Meehan (R-PA) as...
Apr 14 2016
The Rosalind Franklin Award Will Be Presented at the 13th Annual BIO World Congress on Industrial Biotechnology; Winner to Deliver Remarks What:  ...
Apr 13 2016
Washington, D.C. (April 13, 2016) – Millions of farmers around the world have reaped more than US$150 billion in benefits from biotech crops since 1996,...
Apr 12 2016
Washington, D.C. (April 12, 2016) The Biotechnology Innovation Organization (BIO) is pleased to announce that it will be holding an Intellectual Property...
Apr 7 2016
Washington, D.C. (April 07, 2016) – The Biotechnology Innovation Organization (BIO) has announced the elite group of emerging industrial...
Apr 6 2016
Washington, D.C. (April 6, 2016) – Biotechnology Innovation Organization (BIO) President and CEO Jim Greenwood released the following statement regarding...
Apr 5 2016
Today, six biofuel trade associations sent a letter to House and Senate leaders asking Congress for a multiyear extension of advanced biofuel tax credits. The...
Apr 4 2016
Washington, D.C. (April 04, 2016) The Biotechnology Innovation Organization (BIO) is pleased to announce that Europe’s largest cluster of bioeconomy...
Mar 31 2016
Washington, D.C. (March 30, 2016) – The Biotechnology Innovation Organization (BIO) announced today that President and CEO of NexSteppe, Anna...

Biotechnology News

Feb 8 2016 - 12:27pm
BORDEAUX, France & BOSTON--(BUSINESS WIRE)--Regulatory News: IMPLANET (Euronext: IMPL, FR0010458729, PEA-PME eligible), a medical technology company specializing in vertebral and knee-surgery implants, announces the appointment of Brian T. Ennis as President of Implanet America. As such, he will head Implanet America and his objective will be to optimize its organisational structure in order to accelerate the JAZZ technology’s adoption and growth in this vital market. Brian T. Ennis, President

Feb 8 2016 - 12:27pm
LYON, Francia--(BUSINESS WIRE)--ERYTECH (Paris:ERYP) (ADR:EYRYY) (Euronext Paris: FR0011471135 - ERYP), empresa biofarmacéutica francesa dedicada al desarrollo de innovadores tratamientos de inanición de tumores para la leucemia y otras enfermedades oncológicas con necesidades médicas no cubiertas, ha anunciado hoy que Gil Beyen, CEO, y Eric Soyer, CEO y director financiero, realizarán una presentación en la 18ª conferencia anual BIO para CEO e inversores, que tendrá lugar el 8 y 9 de febrero,

Feb 8 2016 - 12:27pm
SEATTLE--(BUSINESS WIRE)--KPI Therapeutics initiates two new lines of research

Feb 8 2016 - 12:27pm
SAINT PREX, Switzerland--(BUSINESS WIRE)--Ferring Pharmaceuticals announced today the commencement of the Phase 3b PRONOUNCE Trial. The trial will compare the occurrence of major adverse cardiovascular events (MACEs) in patients with prostate cancer and cardiovascular disease (CVD), receiving the GnRH receptor antagonist, degarelix, to patients receiving a GnRH receptor agonist, leuprolide. Prostate cancer is the second most common form of cancer in men worldwide with 1.1 million cases diagnose

Feb 8 2016 - 12:27pm
SAINT PREX, Suisse--(BUSINESS WIRE)--Ferring Pharmaceuticals a annoncé aujourd'hui le début de l'essai de Phase 3b, PRONOUNCE. Cet essai comparera la survenance d'événements cardiovasculaires majeurs (MACE) chez des patients atteints d'un cancer de la prostate et de maladie cardiovasculaire recevant l'antagoniste du récepteur de la GnRH, degarelix, et les patients recevant un agoniste de la GnRH, leuprolide. Le cancer de la prostate est la seconde forme de cancer la plus courante chez les homme

Feb 8 2016 - 12:27pm
SAINT PREX, Schweiz--(BUSINESS WIRE)--Ferring Pharmaceuticals gab heute den Beginn der Phase-IIIb-PRONOUNCE-Studie bekannt. Die Studie wird das Auftreten schwerwiegender unerwünschter kardiovaskulärer Ereignisse (MACEs) bei Patienten mit Prostatakrebs und kardiovaskulären Erkrankungen (CVD), die den GnRH-Rezeptor-Antagonisten Degarelix erhalten, mit den MACEs bei Patienten, die den GnRH-Rezeptor-Agonisten Leuprolid erhalten, vergleichen. Prostatakrebs ist die zweithäufigste Form von Krebs bei M

Feb 8 2016 - 12:27pm
SAINT PREX, Suíça--(BUSINESS WIRE)--A Ferring Pharmaceuticals anunciou hoje o começo da Fase 3b do Estudo PRONOUNCE. O estudo irá comparar a ocorrência dos principais eventos cardiovasculares adversos (MACEs) em pacientes com câncer de próstata e doenças cardiovasculares (CVD), recebendo o antagonista receptor GnRH, degarelix, para pacientes recebendo um agonista receptor GnRH, leuprolide. O câncer de próstata é a segunda maior forma comum de câncer em homens em todo o mundo com 1,1 milhão de c

Feb 8 2016 - 12:27pm
SAINT PREX, Svizzera--(BUSINESS WIRE)--Ferring Pharmaceuticals ha annunciato oggi l'inizio dello studio clinico di fase IIIb PRONOUNCE. Lo studio clinico metterà a confronto l'incidenza di eventi avversi cardiovascolari maggiori (MACE, major adverse cardiovascular events) in pazienti affetti da tumore alla prostata e malattie cardiovascolari (MCV), trattati con degarelix, l'antagonista dei recettori GnRH, e in pazienti trattati con leuprolide, un agonista dei recettori GnRH. Il tumore alla pros

Feb 8 2016 - 12:27pm
SAINT PREX, Suiza--(BUSINESS WIRE)--Ferring Pharmaceuticals anunció hoy el comienzo del Estudio PRONOUNCE de Fase 3b. El estudio comparará la ocurrencia de eventos cardiovasculares adversos importantes (por sus siglas en inglés, MACE) en pacientes con cáncer de próstata y enfermedad cardiovascular (por sus siglas en inglés, CVD), que reciben el antagonista del receptor GnRH , degarelix, con pacientes que reciben un agonista del receptor GnRH, leuprolida. El cáncer de próstata es la segunda form

Feb 8 2016 - 12:27pm
DUBLIN--(BUSINESS WIRE)--Research and Markets ( has announced the addition of the "Global Genitourinary Partnering 2010-2016: Deal trends, players and financials" company profile to their offering. Global Genitourinary Partnering 2010 to 2016 provides the full collection of Genitourinary disease deals signed between the world's pharmaceutical and biotechnology companies since 2010. Most of the deals included within the report occur when a